Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEX-AR study of arumakimig in VEXAS syndrome
jRCT2031260375Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of arumakimig in VEXAS syndrome (VEXAS) (2 arms), sponsored by Novartis. Primary endpoint: Number of participants achieving improvement of key VEXAS manifestations and oral glucocorticoid reduction at Week 52. Started Aug 2026; status: recruiting.
02
Drugs
arumakimig
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on jRCT2031260375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260375.